Síndrome de Parkinson e L-dopa Treatment of parkinsonism with L-Dopa

Os autores assinalam o efeito favorável da L-Dopa no tratamento da síndrome parkinsoniana, apresentados por 25 pacientes. Tecem considerações sobre os efeitos colaterais e resultados terapêuticos. Assinalam a presença de eosinofilia após o tratamento em alguns casos e chamam a atenção sobre dois cas...

Full description

Saved in:
Bibliographic Details
Main Authors: Fernando Pompeu, Maier Sztajnberg, Ivan Teixeira, Sérgio Carneiro, Israel Schulz, Sérgio Ribeiro, Hélder Vasconcelos, Edimar Albuquerque
Format: Article
Language:English
Published: Thieme Revinter Publicações 1971-06-01
Series:Arquivos de Neuro-Psiquiatria
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X1971000200005
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Os autores assinalam o efeito favorável da L-Dopa no tratamento da síndrome parkinsoniana, apresentados por 25 pacientes. Tecem considerações sobre os efeitos colaterais e resultados terapêuticos. Assinalam a presença de eosinofilia após o tratamento em alguns casos e chamam a atenção sobre dois casos que tiveram crises convulsivas durante o tratamento.<br>Encouraged by the recent literature on the subject, the authors decided to treat 18 patients in double-blind fashion using L-Dopa against a placebo during 4 weeks. Dosage was gradually increased from 0,5 g to 4 g within this four-week period. Afterwards the trial proceeded openly, all patients receiving L-Dopa. Further 7 patients were added, making up a total number of 25. The trial was carried on for further 8 weeks. Blood counts, liver function tests, urinalysis, ECG and EEG were performed. Eosinophilia, of which the origin could not be ascertained, was found in 8 cases, and generalised convulsions ocurred in two cases. By the 8th week of treatment 6 patients showed marked improvement; 12 had improved noticeably, and the remaining 7 were slightly better. Hyperkinesia and postural hypotension were controlled by dosage reduction. Four patients reported increase of sexual activity. The trial proceeds, a clinical reappraisal being foreseen for the 12th month of. treatment.
ISSN:0004-282X
1678-4227